Incyte's oral MRGPRX2 antagonist INCB187175 emerges from scaffold hybridization
- MRGPRX2 drives IgE-independent mast cell activation and is linked to urticaria, atopic dermatitis and pseudoallergic reactions.
- Scaffold hybridization and SAR gave pyrazolopyrimidine antagonists active in both Gq/IP1 and β-arrestin assays.
- Fixing solubility and CYP inhibition liabilities led to INCB187175, orally exposed across species, which blocked degranulation in primary human mast cells and mast cell activation in vivo.
💡 Points
Scoring on both Gq and β-arrestin readouts is the right call for a receptor where bias could muddy the pharmacology. The solubility and CYP fixes read like a practical optimization story, not a lucky hit. The crowded MRGPRX2 field means the real differentiator will be human exposure and how well mouse-proxy assays translate for a human-restricted receptor.
Discovery of Pyrazolopyrimidines as Potent and Orally Bioavailable MRGPRX2 Antagonists ↗